ESCMID*  ||| S:0 E:8 ||| NNP
guideline  ||| S:8 E:18 ||| NN
for  ||| S:18 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
diagnosis  ||| S:26 E:36 ||| NN
and  ||| S:36 E:40 ||| CC
management  ||| S:40 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
Candida  ||| S:54 E:62 ||| NNP
diseases  ||| S:62 E:71 ||| VBD
2012 ||| S:71 E:75 ||| CD
:  ||| S:75 E:77 ||| :
developing  ||| S:77 E:88 ||| VBG
European  ||| S:88 E:97 ||| JJ
guidelines  ||| S:97 E:108 ||| NNS
in  ||| S:108 E:111 ||| IN
clinical  ||| S:111 E:120 ||| JJ
microbiology  ||| S:120 E:133 ||| NN
and  ||| S:133 E:137 ||| CC
infectious  ||| S:137 E:148 ||| JJ
diseases  ||| S:148 E:157 ||| NNS
The  ||| S:157 E:161 ||| DT
process  ||| S:161 E:169 ||| NN
to  ||| S:169 E:172 ||| TO
develop  ||| S:172 E:180 ||| VB
a  ||| S:180 E:182 ||| DT
guideline  ||| S:182 E:192 ||| NN
in  ||| S:192 E:195 ||| IN
a  ||| S:195 E:197 ||| DT
European  ||| S:197 E:206 ||| JJ
setting  ||| S:206 E:214 ||| NN
remains  ||| S:214 E:222 ||| VBZ
a  ||| S:222 E:224 ||| DT
challenge ||| S:224 E:233 ||| NN
.  ||| S:233 E:235 ||| .
The  ||| S:235 E:239 ||| DT
ESCMID  ||| S:239 E:246 ||| NNP
Fungal  ||| S:246 E:253 ||| NNP
Infection  ||| S:253 E:263 ||| NNP
Study  ||| S:263 E:269 ||| NNP
Group  ||| S:269 E:275 ||| NNP
( ||| S:275 E:276 ||| -LRB-
EFISG ||| S:276 E:281 ||| NNP
)  ||| S:281 E:283 ||| -RRB-
successfully  ||| S:283 E:296 ||| RB
achieved  ||| S:296 E:305 ||| VBN
this  ||| S:305 E:310 ||| DT
endeavour ||| S:310 E:319 ||| NN
.  ||| S:319 E:321 ||| .
After  ||| S:321 E:327 ||| IN
two  ||| S:327 E:331 ||| CD
face-to-face  ||| S:331 E:344 ||| JJ
meetings ||| S:344 E:352 ||| NNS
,  ||| S:352 E:354 ||| ,
numerous  ||| S:354 E:363 ||| JJ
telephone  ||| S:363 E:373 ||| NN
conferences ||| S:373 E:384 ||| NNS
,  ||| S:384 E:386 ||| ,
and  ||| S:386 E:390 ||| CC
email  ||| S:390 E:396 ||| JJ
correspondence ||| S:396 E:410 ||| NN
,  ||| S:410 E:412 ||| ,
an  ||| S:412 E:415 ||| DT
ESCMID  ||| S:415 E:422 ||| NNP
task  ||| S:422 E:427 ||| NN
force  ||| S:427 E:433 ||| NN
( ||| S:433 E:434 ||| -LRB-
basically  ||| S:434 E:444 ||| RB
composed  ||| S:444 E:453 ||| VBN
of  ||| S:453 E:456 ||| IN
members  ||| S:456 E:464 ||| NNS
of  ||| S:464 E:467 ||| IN
the  ||| S:467 E:471 ||| DT
Society ||| S:471 E:478 ||| NNP
's  ||| S:478 E:481 ||| POS
Fungal  ||| S:481 E:488 ||| NNP
Infection  ||| S:488 E:498 ||| NNP
Study  ||| S:498 E:504 ||| NNP
Group ||| S:504 E:509 ||| NNP
,  ||| S:509 E:511 ||| ,
EFISG ||| S:511 E:516 ||| NNP
)  ||| S:516 E:518 ||| -RRB-
finalized  ||| S:518 E:528 ||| VBD
the  ||| S:528 E:532 ||| DT
ESCMID  ||| S:532 E:539 ||| NNP
diagnostic  ||| S:539 E:550 ||| JJ
and  ||| S:550 E:554 ||| CC
management ||| S:554 E:564 ||| NN
/ ||| S:564 E:565 ||| CD
therapeutic  ||| S:565 E:577 ||| JJ
guideline  ||| S:577 E:587 ||| NN
for  ||| S:587 E:591 ||| IN
Candida  ||| S:591 E:599 ||| NNP
diseases ||| S:599 E:607 ||| NNS
.  ||| S:607 E:609 ||| .
By  ||| S:609 E:612 ||| IN
appreciating  ||| S:612 E:625 ||| VBG
various  ||| S:625 E:633 ||| JJ
patient  ||| S:633 E:641 ||| NN
populations  ||| S:641 E:653 ||| NNS
at  ||| S:653 E:656 ||| IN
risk  ||| S:656 E:661 ||| NN
for  ||| S:661 E:665 ||| IN
Candida  ||| S:665 E:673 ||| NNP
diseases ||| S:673 E:681 ||| NNS
,  ||| S:681 E:683 ||| ,
four  ||| S:683 E:688 ||| CD
subgroups  ||| S:688 E:698 ||| NNS
were  ||| S:698 E:703 ||| VBD
predefined ||| S:703 E:713 ||| CD
,  ||| S:713 E:715 ||| ,
mainly  ||| S:715 E:722 ||| RB
ICU  ||| S:722 E:726 ||| JJ
patients ||| S:726 E:734 ||| NNS
,  ||| S:734 E:736 ||| ,
paediatric ||| S:736 E:746 ||| NN
,  ||| S:746 E:748 ||| ,
HIV ||| S:748 E:751 ||| NNP
/ ||| S:751 E:752 ||| NNP
AIDS  ||| S:752 E:757 ||| NNP
and  ||| S:757 E:761 ||| CC
patients  ||| S:761 E:770 ||| NNS
with  ||| S:770 E:775 ||| IN
malignancies  ||| S:775 E:788 ||| NNS
including  ||| S:788 E:798 ||| VBG
haematopoietic  ||| S:798 E:813 ||| JJ
stem  ||| S:813 E:818 ||| NN
cell  ||| S:818 E:823 ||| NN
transplantation ||| S:823 E:838 ||| NN
.  ||| S:838 E:840 ||| .
Besides  ||| S:840 E:848 ||| IN
treatment  ||| S:848 E:858 ||| NN
recommendations ||| S:858 E:873 ||| NNS
,  ||| S:873 E:875 ||| ,
the  ||| S:875 E:879 ||| DT
ESCMID  ||| S:879 E:886 ||| NNP
guidelines  ||| S:886 E:897 ||| NNS
provide  ||| S:897 E:905 ||| VBP
guidance  ||| S:905 E:914 ||| VBN
for  ||| S:914 E:918 ||| IN
diagnostic  ||| S:918 E:929 ||| JJ
procedures ||| S:929 E:939 ||| NNS
.  ||| S:939 E:941 ||| .
For  ||| S:941 E:945 ||| IN
the  ||| S:945 E:949 ||| DT
guidelines ||| S:949 E:959 ||| NNS
,  ||| S:959 E:961 ||| ,
questions  ||| S:961 E:971 ||| NNS
were  ||| S:971 E:976 ||| VBD
formulated  ||| S:976 E:987 ||| VBN
to  ||| S:987 E:990 ||| TO
phrase  ||| S:990 E:997 ||| VB
the  ||| S:997 E:1001 ||| DT
intention  ||| S:1001 E:1011 ||| NN
of  ||| S:1011 E:1014 ||| IN
a  ||| S:1014 E:1016 ||| DT
given  ||| S:1016 E:1022 ||| VBN
recommendation ||| S:1022 E:1036 ||| NN
,  ||| S:1036 E:1038 ||| ,
for  ||| S:1038 E:1042 ||| IN
example ||| S:1042 E:1049 ||| NN
,  ||| S:1049 E:1051 ||| ,
outcome ||| S:1051 E:1058 ||| NN
.  ||| S:1058 E:1060 ||| .
The  ||| S:1060 E:1064 ||| DT
recommendation  ||| S:1064 E:1079 ||| NN
was  ||| S:1079 E:1083 ||| VBD
the  ||| S:1083 E:1087 ||| DT
clinical  ||| S:1087 E:1096 ||| JJ
intervention ||| S:1096 E:1108 ||| NN
,  ||| S:1108 E:1110 ||| ,
which  ||| S:1110 E:1116 ||| WDT
was  ||| S:1116 E:1120 ||| VBD
graded  ||| S:1120 E:1127 ||| VBN
by  ||| S:1127 E:1130 ||| IN
a  ||| S:1130 E:1132 ||| DT
score  ||| S:1132 E:1138 ||| NN
of  ||| S:1138 E:1141 ||| IN
A-D  ||| S:1141 E:1145 ||| NNP
for  ||| S:1145 E:1149 ||| IN
the  ||| S:1149 E:1153 ||| DT
' ||| S:1153 E:1154 ||| POS
Strength  ||| S:1154 E:1163 ||| NNP
of  ||| S:1163 E:1166 ||| IN
a  ||| S:1166 E:1168 ||| DT
recommendation ||| S:1168 E:1182 ||| NN
' ||| S:1182 E:1183 ||| POS
.  ||| S:1183 E:1185 ||| .
The  ||| S:1185 E:1189 ||| NNP
' ||| S:1189 E:1190 ||| POS
level  ||| S:1190 E:1196 ||| NN
of  ||| S:1196 E:1199 ||| IN
evidence ||| S:1199 E:1207 ||| NN
'  ||| S:1207 E:1209 ||| POS
received  ||| S:1209 E:1218 ||| VBD
a  ||| S:1218 E:1220 ||| DT
score  ||| S:1220 E:1226 ||| NN
of  ||| S:1226 E:1229 ||| IN
I-III ||| S:1229 E:1234 ||| JJ
.  ||| S:1234 E:1236 ||| .
The  ||| S:1236 E:1240 ||| DT
author  ||| S:1240 E:1247 ||| NN
panel  ||| S:1247 E:1253 ||| NN
was  ||| S:1253 E:1257 ||| VBD
approved  ||| S:1257 E:1266 ||| VBN
by  ||| S:1266 E:1269 ||| IN
ESCMID ||| S:1269 E:1275 ||| NNP
,  ||| S:1275 E:1277 ||| ,
European  ||| S:1277 E:1286 ||| NNP
Organisation  ||| S:1286 E:1299 ||| NNP
for  ||| S:1299 E:1303 ||| IN
Research  ||| S:1303 E:1312 ||| NNP
and  ||| S:1312 E:1316 ||| CC
Treatment  ||| S:1316 E:1326 ||| NNP
of  ||| S:1326 E:1329 ||| IN
Cancer ||| S:1329 E:1335 ||| NNP
,  ||| S:1335 E:1337 ||| ,
European  ||| S:1337 E:1346 ||| NNP
Group  ||| S:1346 E:1352 ||| NNP
for  ||| S:1352 E:1356 ||| IN
Blood  ||| S:1356 E:1362 ||| NNP
and  ||| S:1362 E:1366 ||| CC
Marrow  ||| S:1366 E:1373 ||| NNP
Transplantation ||| S:1373 E:1388 ||| NNP
,  ||| S:1388 E:1390 ||| ,
European  ||| S:1390 E:1399 ||| NNP
Society  ||| S:1399 E:1407 ||| NNP
of  ||| S:1407 E:1410 ||| IN
Intensive  ||| S:1410 E:1420 ||| NNP
Care  ||| S:1420 E:1425 ||| NNP
Medicine  ||| S:1425 E:1434 ||| NNP
and  ||| S:1434 E:1438 ||| CC
the  ||| S:1438 E:1442 ||| DT
European  ||| S:1442 E:1451 ||| NNP
Confederation  ||| S:1451 E:1465 ||| NNP
of  ||| S:1465 E:1468 ||| IN
Medical  ||| S:1468 E:1476 ||| NNP
Mycology ||| S:1476 E:1484 ||| NNP
.  ||| S:1484 E:1486 ||| .
The  ||| S:1486 E:1490 ||| DT
guidelines  ||| S:1490 E:1501 ||| NNS
followed  ||| S:1501 E:1510 ||| VBD
the  ||| S:1510 E:1514 ||| DT
framework  ||| S:1514 E:1524 ||| NN
of  ||| S:1524 E:1527 ||| IN
GRADE  ||| S:1527 E:1533 ||| NNP
and  ||| S:1533 E:1537 ||| CC
Appraisal  ||| S:1537 E:1547 ||| NNP
of  ||| S:1547 E:1550 ||| IN
Guidelines ||| S:1550 E:1560 ||| NNP
,  ||| S:1560 E:1562 ||| ,
Research ||| S:1562 E:1570 ||| NNP
,  ||| S:1570 E:1572 ||| ,
and  ||| S:1572 E:1576 ||| CC
Evaluation ||| S:1576 E:1586 ||| NNP
.  ||| S:1586 E:1588 ||| .
The  ||| S:1588 E:1592 ||| DT
drafted  ||| S:1592 E:1600 ||| JJ
guideline  ||| S:1600 E:1610 ||| NN
was  ||| S:1610 E:1614 ||| VBD
presented  ||| S:1614 E:1624 ||| VBN
at  ||| S:1624 E:1627 ||| IN
ECCMID  ||| S:1627 E:1634 ||| NNP
2011  ||| S:1634 E:1639 ||| CD
and  ||| S:1639 E:1643 ||| CC
points  ||| S:1643 E:1650 ||| NNS
of  ||| S:1650 E:1653 ||| IN
discussion  ||| S:1653 E:1664 ||| NN
occurring  ||| S:1664 E:1674 ||| VBG
during  ||| S:1674 E:1681 ||| IN
that  ||| S:1681 E:1686 ||| DT
meeting  ||| S:1686 E:1694 ||| NN
were  ||| S:1694 E:1699 ||| VBD
incorporated  ||| S:1699 E:1712 ||| VBN
into  ||| S:1712 E:1717 ||| IN
the  ||| S:1717 E:1721 ||| DT
manuscripts ||| S:1721 E:1732 ||| NN
.  ||| S:1732 E:1734 ||| .
These  ||| S:1734 E:1740 ||| DT
ESCMID  ||| S:1740 E:1747 ||| NNP
guidelines  ||| S:1747 E:1758 ||| NNS
for  ||| S:1758 E:1762 ||| IN
the  ||| S:1762 E:1766 ||| DT
diagnosis  ||| S:1766 E:1776 ||| NN
and  ||| S:1776 E:1780 ||| CC
management  ||| S:1780 E:1791 ||| NN
of  ||| S:1791 E:1794 ||| IN
Candida  ||| S:1794 E:1802 ||| NNP
diseases  ||| S:1802 E:1811 ||| NNS
provide  ||| S:1811 E:1819 ||| VBP
guidance  ||| S:1819 E:1828 ||| VBN
for  ||| S:1828 E:1832 ||| IN
clinicians  ||| S:1832 E:1843 ||| NN
in  ||| S:1843 E:1846 ||| IN
their  ||| S:1846 E:1852 ||| PRP$
daily  ||| S:1852 E:1858 ||| JJ
decision-making  ||| S:1858 E:1874 ||| JJ
process ||| S:1874 E:1881 ||| NN
.  ||| S:1881 E:1883 ||| .
